• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688105.SS
Share

Nanjing Vazyme Biotech Co., Ltd Stocks

CN¥ 19.2Last Updated 15.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.38B

CN¥ 19.2
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nanjing Vazyme Biotech Co., Ltd., a prominent biotechnology firm, specializes in the comprehensive investigation, development, and manufacturing of essential biological components. These core offerings include enzymes, antigens, antibodies, and unique polymer organic compounds. The company's extensive product portfolio encompasses a broad spectrum of scientific research reagents. This range features solutions for advanced techniques such as PCR cloning and point mutation, nucleic acid extraction, reverse transcription, quantitative PCR (qPCR), cell and protein analysis, gene editing applications, and user-friendly instant granule formulations. Furthermore, Vazyme provides sophisticated reagents crucial for high-throughput sequencing library construction, including those for DNA and RNA library preparation, single-cell epigenetics, magnetic bead-based methodologies, quantitative assays, and the effective storage and extraction of cell-free DNA. Complementing these, the company also delivers a variety of biomedical reagents and related services. Vazyme's diverse clientele spans scientific research institutions, specialized high-throughput sequencing service providers, manufacturers of molecular diagnostic reagents, pharmaceutical enterprises, contract research organizations (CROs), hospitals, and other healthcare facilities. Established in 2012, the company maintains its headquarters in Nanjing, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 16:35

The stock price of Stride, a small edtech company, has plummeted. The reason is Anthropic

15.07.2026 16:00

"There Aren't Enough IT Budgets to Go Around": What Does IBM's Historic Plunge Mean for the Stock Market?

15.07.2026 15:46

Morning in New York: New inflation data will set the tone for trading

15.07.2026 14:33

Where to Invest $1,000 Right Now: 4 Stocks to Consider in the Third Quarter

15.07.2026 13:49

Apple has found a startup that reduces the size of AI models. This could help it improve Siri

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026